Table 6.18 Probability of success and failures at interim and final analysis after calibrating type I error rate in the half adaptive design (Scenario 3) A: Bayesian model (Type I error rate was calibrated at 5%) Emax True Dose Response Bayesian model Emax Early Early Final Final Mean Total success failure success failure subjects Success 5% Placebo like flat curve 0.00 0.27 0.05 0.68 60.7 99% curve 0.79 0.00 0.20 0.01 55.6 Emax 97% Log Linear Curve 0.66 0.00 0.31 0.03 57.7 19% U Shaped curve 0.06 0.11 0.13 0.70 61.9 B. Bayesian NDLM (Type I error rate was calibrated at 5%) True Dose Response Bayesian NDLM model Early Early Final Final Mean Total success failure success failure subjects Success Placebo like flat curve 0.00 0.21 0.05 0.74 5% 62.8 curve 0.70 0.00 0.18 0.11 57.6 Emax 88% Log Linear Curve 0.62 0.02 0.20 0.25 57.8 82% U Shaped curve 0.53 0.00 0.21 0.17 58.0 74%
Table 6.18 Probability of success and failures at interim and final analysis after calibrating type I error rate in the half adaptive design (Scenario 3) A: Bayesian Emax model (Type I error rate was calibrated at 5%) True Dose Response Bayesian Emax model Early success Early failure Final success Final failure Total Success Mean subjects Placebo like flat curve 0.00 0.27 0.05 0.68 5% 60.7 Emax curve 0.79 0.00 0.20 0.01 99% 55.6 Log Linear Curve 0.66 0.00 0.31 0.03 97% 57.7 U Shaped curve 0.06 0.11 0.13 0.70 19% 61.9 B. Bayesian NDLM (Type I error rate was calibrated at 5%) True Dose Response Bayesian NDLM model Early success Early failure Final success Final failure Total Success Mean subjects Placebo like flat curve 0.00 0.21 0.05 0.74 5% 62.8 Emax curve 0.70 0.00 0.18 0.11 88% 57.6 Log Linear Curve 0.62 0.02 0.20 0.25 82% 57.8 U Shaped curve 0.53 0.00 0.21 0.17 74% 58.0
PhD%20Dissertation%20Feng%20Liu%20Final%20Clean.docx